<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001932</url>
  </required_header>
  <id_info>
    <org_study_id>H 18058722</org_study_id>
    <nct_id>NCT05001932</nct_id>
  </id_info>
  <brief_title>Optimizing Refractive Results and Patient Satisfaction After Cataract Surgery</brief_title>
  <acronym>ORAPSCA</acronym>
  <official_title>Optimizing Refractive Results and Patient Satisfaction After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cataract surgery is the most common eye surgery in the world. If the patient with cataract&#xD;
      uses spectacles and both patient and surgeon find it beneficial, it is possible to compensate&#xD;
      for the spectacles during surgery and thereby obtain a spectacle-free distance vision or&#xD;
      spectacle-free near vision. Becoming spectacle free increases quality of life substantially&#xD;
      and is one of the primary wishes in cataract patients. Socioeconomically, spectacle free life&#xD;
      is beneficial as it reduces fall tendency in the elderly population. Multifocal lenses&#xD;
      warrant the possibility of obtaining a spectacle free vision at near, intermediate and&#xD;
      distance. It is also possible to obtain spectacle free distance and near vision or distance&#xD;
      and intermediate vision by using traditional artificial monofocal lenses but making one eye&#xD;
      spectacle free for distance and the other eye spectacle free for near or intermediate vision.&#xD;
      Currently, it is not know which procedure is most beneficial for cataract patients.&#xD;
&#xD;
      In a recent PhD, the investigators developed a method, Aniseikonia Tolerance Range (ATR),&#xD;
      that can assess how much refractive change a patient can endure without impairing stereopsis.&#xD;
      The results demonstrated large variation in the tolerance of image difference. This method&#xD;
      can be a future tool to assess whether a patient can tolerate the refraction that is&#xD;
      considered most beneficial to the patient. The knowledge is important as it can help avoid&#xD;
      improper lens choice in cataract surgery and thereby avoid stereopsis problems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background This randomized clinical trial aims to improve visual outcomes in cataract surgery&#xD;
      by examining which intraocular lenses (IOL)/operation methods that provide highest patient&#xD;
      satisfaction, visual function and spectacle free vision. Furthermore, the tolerance of&#xD;
      surgical induced refractive difference (anisometropia) will be examined and a screening&#xD;
      method to assess how much anisometropia a patient can endure will be validated. The&#xD;
      investigators will examine if the tolerance of anisometropia &gt; 3 diopters is better than&#xD;
      previously described and examine if ATR can predict which patients will experience binocular&#xD;
      problems if exposed to surgical induced aniseikonia.These results will lead to higher patient&#xD;
      satisfaction, better visual outcomes with elimination of patients with mediocre refractive&#xD;
      results and visual problems due to anisometropia.&#xD;
&#xD;
      In addition the investigators will examine whether ATR is reproducible by examining the&#xD;
      variation in the multiple measurements and in a prospective study the investigators will&#xD;
      investigate the inter and intra person reproducibility of ATR.&#xD;
&#xD;
      100 refractive patients with healthy eyes except myopia &gt; 3 diopters and &lt; 6 diopters, who&#xD;
      will have a Small Incision Lenticule Extraction (SMILE) surgery will have all investigations&#xD;
      done. The patients will have a bilateral SMILE with a interval of seven weeks and will in&#xD;
      between the two procedures have a surgically introduced anisometropia that will provide&#xD;
      further knowledge on anisometropia and ATR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>120 days</time_frame>
    <description>Investigate if MIOLs, mono-vision and mini-vision provides better visual function, quality of vision and spectacle free vision compared to monofocal IOLs. This will be evaluated by questionnaires and objective measurements as described.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of anisometropia</measure>
    <time_frame>120 days</time_frame>
    <description>Investigate if the tolerance of anisometropia is better in the elderly population compared to a younger population (SMILE patients). This will be evaluated by questionnaires and objective measurements as described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aniseikonia tolerance range (ATR)</measure>
    <time_frame>120 days</time_frame>
    <description>Compare ATR in all four arms and in a SMILE population to investigate if ATR is a future screening tool that can predict which patients cannot tolerate anisometropia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aniseikonia tolerance range (ATR)</measure>
    <time_frame>120 days</time_frame>
    <description>Investigate if ATR is reproducible and clinical useful in cataract patients with poor vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anisometropia</measure>
    <time_frame>120 days</time_frame>
    <description>Investigate if anisometropia &gt; 3 diopters are better tolerated than previously described. This will be evaluated by questionnaires and objective measurements as described.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Multifocal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a multifocal lens bilateral (Alcon Vivity).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mono-vision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant myopia of -2.50D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimono-vision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a monofocal lens bilateral. Target refraction for the dominant eye will be -0.25D and for the non-dominant -1.25D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monofocal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a monofocal lens bilateral. Target refraction will be -0.25D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Randomized Clinical Trial</description>
    <arm_group_label>Minimono-vision</arm_group_label>
    <arm_group_label>Mono-vision</arm_group_label>
    <arm_group_label>Monofocal</arm_group_label>
    <arm_group_label>Multifocal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bilateral cataract&#xD;
&#xD;
          -  Axial length: 20-27 mm&#xD;
&#xD;
          -  ACD &gt; 2.3 mm&#xD;
&#xD;
          -  Pupil size: ≥ 5.0 mm in dilatation&#xD;
&#xD;
          -  Pupil siza: ≥ 2.5 mm in photo topic condition&#xD;
&#xD;
          -  Stereoacuity ≤ 480 seconds of arch&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Former intraocular surgery&#xD;
&#xD;
          -  Other eye disease (amblyopia, strabismus, corneal pathology, glaucoma, uveitis, age&#xD;
             related maculopathy&#xD;
&#xD;
          -  Other retinal diseases&#xD;
&#xD;
          -  Risk of weak zonules due to PEX or former trauma&#xD;
&#xD;
          -  Astigmatism ≥ 1.0 diopter&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Axial length difference between the two eyes &gt; 0.3 mm&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Lack of cooperation kooperation&#xD;
&#xD;
          -  Stereoacuity &gt; 480 seconds of arc&#xD;
&#xD;
          -  Complicated cataract surgery or postoperative complications (intraocular infection,&#xD;
             retinal detachment, macular edema&#xD;
&#xD;
          -  Business driving&#xD;
&#xD;
          -  Night driving&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten la Cour, MD, prof.</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Glostrup</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Guldhammer Skov, MD</last_name>
    <phone>+45 38 63 38 63</phone>
    <email>anne.guldhammer.skov.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet - Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Guldhammer Skov, MD</last_name>
      <phone>+4538634707</phone>
      <email>anne.guldhammer.skov.01@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anne Guldhammer Skov, MD</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Anisometropia</keyword>
  <keyword>Aniseikonia Tolerance Range</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

